- Home
- EPRX vs GUTS Comparison
EPRX vs GUTS Comparison
Compare EPRX & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPRX
- GUTS
- Stock Information
- Founded
- EPRX 2011
- GUTS 2010
- Country
- EPRX Canada
- GUTS United States
- Employees
- EPRX N/A
- GUTS N/A
- Industry
- EPRX
- GUTS
- Sector
- EPRX
- GUTS
- Exchange
- EPRX NYSE
- GUTS NYSE
- Market Cap
- EPRX 109.7M
- GUTS 110.1M
- IPO Year
- EPRX N/A
- GUTS 2024
- Fundamental
- Price
- EPRX $3.20
- GUTS $1.80
- Analyst Decision
- EPRX Strong Buy
- GUTS Buy
- Analyst Count
- EPRX 1
- GUTS 2
- Target Price
- EPRX $9.00
- GUTS $18.00
- AVG Volume (30 Days)
- EPRX 6.9K
- GUTS 382.2K
- Earning Date
- EPRX 02-07-2025
- GUTS 02-02-2025
- Dividend Yield
- EPRX N/A
- GUTS N/A
- EPS Growth
- EPRX N/A
- GUTS N/A
- EPS
- EPRX N/A
- GUTS N/A
- Revenue
- EPRX N/A
- GUTS $97,000.00
- Revenue This Year
- EPRX N/A
- GUTS N/A
- Revenue Next Year
- EPRX N/A
- GUTS N/A
- P/E Ratio
- EPRX N/A
- GUTS N/A
- Revenue Growth
- EPRX N/A
- GUTS N/A
- 52 Week Low
- EPRX $2.20
- GUTS $1.74
- 52 Week High
- EPRX $4.08
- GUTS $14.50
- Technical
- Relative Strength Index (RSI)
- EPRX N/A
- GUTS 40.50
- Support Level
- EPRX N/A
- GUTS $1.91
- Resistance Level
- EPRX N/A
- GUTS $2.10
- Average True Range (ATR)
- EPRX 0.00
- GUTS 0.16
- MACD
- EPRX 0.00
- GUTS -0.01
- Stochastic Oscillator
- EPRX 0.00
- GUTS 6.12
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.